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Matthew J. Mulcahy1, Bruce Cohen1, Saidhbhe L. O'Riordan1, Charlene Kim1, Dennis A. Dougherty4, Edwin R. Chapman3, Jonathan S. Marvin2,
Loren L. Looger2, and Henry A. Lester1,2
Nicotine dependence is thought to arise in part because nicotine permeates into the endoplasmic reticulum (ER), where it
binds to nicotinic receptors (nAChRs) and begins an “inside-out” pathway that leads to up-regulation of nAChRs on the plasma
membrane. However, the dynamics of nicotine entry into the ER are unquantiﬁed. Here, we develop a family of genetically
encoded ﬂuorescent biosensors for nicotine, termed iNicSnFRs. The iNicSnFRs are fusions between two proteins: a circularly
permutated GFP and a periplasmic choline-/betaine-binding protein engineered to bind nicotine. The biosensors iNicSnFR3a and
iNicSnFR3b respond to nicotine by increasing ﬂuorescence at [nicotine] <1 µM, the concentration in the plasma and
cerebrospinal ﬂuid of a smoker. We target iNicSnFR3 biosensors either to the plasma membrane or to the ER and measure
nicotine kinetics in HeLa, SH-SY5Y, N2a, and HEK293 cell lines, as well as mouse hippocampal neurons and human stem
cell–derived dopaminergic neurons. In all cell types, we ﬁnd that nicotine equilibrates in the ER within 10 s (possibly within
1 s) of extracellular application and leaves as rapidly after removal from the extracellular solution. The [nicotine] in the ER is
within twofold of the extracellular value. We use these data to run combined pharmacokinetic and pharmacodynamic
simulations of human smoking. In the ER, the inside-out pathway begins when nicotine becomes a stabilizing
pharmacological chaperone for some nAChR subtypes, even at concentrations as low as ∼10 nM. Such concentrations would
persist during the 12 h of a typical smoker’s day, continually activating the inside-out pathway by >75%. Reducing nicotine
intake by 10-fold decreases activation to ∼20%. iNicSnFR3a and iNicSnFR3b also sense the smoking cessation drug
varenicline, revealing that varenicline also permeates into the ER within seconds. Our iNicSnFRs enable optical subcellular
pharmacokinetics for nicotine and varenicline during an early event in the inside-out pathway.
Introduction
Existing data show that nicotine evokes two processes at neu-
ronal nicotinic acetylcholine (ACh) receptors (nAChRs). His-
torically, the best-characterized process is activation of nAChRs
on the plasma membrane (PM). If one considers events at the
scale of a neuron, activation of nAChRs at the PMmay be termed
the “outside-in” pathway. Like activation by the endogenous
neurotransmitter ACh, activation by exogenous nicotine via the
outside-in activation pathway involves an inﬂux of Na+ and Ca2+
ions, depolarization and therefore increased frequency of neu-
ronal action potentials. The outside-in pathway, and perhaps the
subsequent desensitization of nAChRs, leads to the acute effects
after nicotine enters the airways either from tobacco combus-
tion (smoking) or from an electronic nicotine delivery system
(ENDS; “vaping”). These acute effects, beginning within <1 min
after inhalation and lasting for dozens ofminutes include a sense
of well-being, a cognitive boost, appetite suppression, increased
tolerance of stressful stimuli, and suppression of withdrawal
(Miwa et al., 2011; Naude´ et al., 2015; Nees, 2015; Picciotto et al.,
2015).
Since approximately 2005, evidence has been accumulating
for a second process. We term this the “inside-out” pathway,
because it begins when nicotine permeates into the ER. In the
ER, nicotine binds to nascent nAChRs and becomes a stabilizing
pharmacological chaperone for α4- and β2-subunit–containing
(α4β2*) nAChRs, increasing their exit from the ER (Fig. 1 A;
Kuryatov et al., 2005; Sallette et al., 2005; Lester et al., 2009).
The inside-out pathway leads to up-regulation of nAChRs on the
PM. The inside-out pathway results, jointly, from three prop-
erties (Fig. 1 A). (1) Like ACh, nicotine activates nAChRs (a
pharmacological property). (2) In contrast to ACh, nicotine has a
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neutral, membrane-permeant form (a pharmacokinetic prop-
erty). (3) In contrast to hydrolysis of ACh within <1 ms by Ach
sterase, catabolic oxidation of nicotine proceeds on a time scale
of ∼30 min, primarily by cytochrome P450 (another pharma-
cokinetic property; Henderson and Lester, 2015; Tanner et al.,
2015).
The research community has not yet reported decisive tests
for the relative importance of the inside-out and outside-in
pathways in nicotine dependence. Several laboratories are
testing the hypothesis that the selective up-regulation of speciﬁc
nAChR subtypes via the inside-out pathway is necessary and
sufﬁcient for some early events (days to weeks) of nicotine de-
pendence (Govind et al., 2009; Henderson and Lester, 2015).
Nicotine-induced up-regulation of nAChRs via chaperoning is
post-translational, involving neither gene activation nor mRNA
stability of nAChR subunits (Henderson and Lester, 2015).
A satisfactory comparison of the outside-in and inside-out
pathways during smoking/vaping has been hampered by lack
of information about the pharmacokinetics of nicotine at the
subcellular scale: How long does it take nicotine to permeate into
the ER, and what is its concentration there (Lester et al., 2009;
Rollema et al., 2010; Hussmann et al., 2012)? Previous data show
that, when nicotine is applied for more than several hours, it up-
regulates nAChRs. This up-regulation has an EC50 of ∼30 nM
(Kuryatov et al., 2005). It has not been known (1) whether
nicotine concentration in the ER reaches the EC50 for up-
regulation; (2) if so, how quickly; and (3) how quickly nicotine
leaves the ER.
To approach these questions quantitatively, we have devel-
oped a series of genetically encoded intensity-based nicotine-
sensing ﬂuorescent reporters (iNicSnFRs). These biosensors
comprise a fusion between a bacterial periplasmic-binding
protein (PBP) moiety (276 amino acids), a circularly permuted
GFP (cpGFP) moiety (244 amino acids), joining regions (“link-
ers”), and epitope tags. The development of the glutamate bio-
sensor iGluSnFR (Marvin et al., 2013) has provided a model for
this study. We report on use of a novel PBP moiety and on
mutations that allow the PBP moiety of the biosensor to bind
nicotine. We have directed these iNicSnFRs either to the PM (at
the start of the outside-in pathway) or to the lumen of the ER (at
the start of the inside-out pathway; Fig. 1 B). We have also
veriﬁed the compartmentalization of the iNicSnFRs by showing
that the ﬂuorescence response to nicotine contrasts with re-
sponses to membrane-impermeant quaternary amines (Fig. 1 C).
Smoking cessation has become desirable for individual health
and for public health (Royal College of Physicians, 2016). Vare-
nicline (shown in Fig. 1 A), a partial agonist for α4β2 nAChRs and
full agonist for α7 nAChRs, is now the most effective synthetic
drug for smoking cessation. Nonetheless, varenicline therapy
succeeds in only a minority of people who aspire to quit smoking
(Fagerstro¨m and Hughes, 2008). Varenicline also permeates
modestly well into the central nervous system (Rollema et al.,
2010). Varenicline has a half-life of ∼24 h in human plasma
(Faessel et al., 2006) and presumably in human brain. Exposure
to varenicline also up-regulates α4β2 nAChRs (Turner et al.,
2011; Marks et al., 2015; Govind et al., 2017), an indication that
it too participates in the inside-out pathway. We therefore
sought to determine whether varenicline also enters the ER and,
if so, how much and how quickly. Serendipitously, an iNicSnFR
also binds to and senses varenicline, and we suggest how vare-
nicline’s entry into the ER may limit its therapeutic actions.
Materials and methods
Directed evolution of iNicSnFR proteins using
bacterial-expressed protein assays
The Results section, below, begins by describing the overall
strategy in constructing the iNicSnFRs. Class F PBPs consist of
two domains that move relative to each other when the ligand
binds at the interdomain interface (Berntsson et al., 2010).
Previous biosensor constructs have placed a cpGFP molecule
within the PBP. We constructed and measured ∼12,000 mutants
iteratively, using ﬂuorescence measurements as described be-
low. We incorporated four additional linker1 residues before the
N terminus of the “superfolder” cpGFP gene (Pe´delacq et al.,
2006; Marvin et al., 2018) and four additional linker2 residues
Figure 1. Strategy of the experiments. (A) Nicotine (pKa, 7.5–8.1) and
varenicline (pKa, 9.5–10) are weak bases. They interconvert on a millisecond
time scale between protonated and deprotonated forms; these are respec-
tively membrane impermeant and permeant. (B) The tactic of conﬁning a
genetically encoded ﬂuorescent nicotinic drug sensor to the PM or the ER. (C)
Choline, ACh, and N’MeNic exist only as charged, membrane-impermeant
forms near physiological pH.
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after the C terminus of the superfolder cpGFP, because this
cpGFP variant functions well in the ER (Aronson et al., 2011). We
inserted linker1-cpGFP-linker2 at candidate positions within
OpuBC sequence at positions near the interdomain interface of
the PBP, based on previous structural data cited in Results for
choline- and betaine-binding class F PBPs. We optimized linker1
and linker2 with site-saturated mutagenesis (SSM).
The ligand-binding site (originally for choline and/or beta-
ine) lies at the interdomain interface of the PBP. To optimize the
ligand site for nicotine, we performed SSM on several residues
near the possible cation-π residues (ﬁrst-shell residues that lie
within 7 A˚ of the ligand binding pocket; Fig. S1), as well as on
“second-shell” residues (residues that showed intraprotein in-
teractions with the ﬁrst-shell residues). Mutagenesis was per-
formed by slight modiﬁcations to the Quikchange mutagenesis
protocol (Agilent). Each round of SSM used NN(C/G) oligonu-
cleotides that provided > 96% residue coverage for a collection of
188 randomly chosen clones.
One design goal was a 30% increase in ﬂuorescence (ΔF/F0 =
0.3) at [nicotine] = 1 µM, a concentration thought to lie in the
range of the peak [nicotine] in the plasma and brain of a smoker
(Benowitz et al., 1991; Rollema et al., 2010). In preliminary
characterization, lysates were tested with excitation at 485 nm
and emission at 535 nm. Automated 96-well ﬂuorescence plate
readers were used to measure resting and nicotine-induced
ﬂuorescence (F0 and ΔF, respectively; Tecan M1000, equipped
with monocomators; and Tecan Spark M10, equipped with ﬁl-
ters). Promising clones were ampliﬁed and sequenced. The
beneﬁcial substitutions identiﬁed were combined with side-
directed mutagenesis (SDM), and the “best” combination in
each round of evolution was used as a template for the next
round of SSM (Fig. S2).
We conducted one or more rounds of SSM experiments at
each of the 25 codons shown in Fig. S1. In sum, these experi-
ments improved the ΔF/F0 at 1 µM nicotine by a factor ∼105
(Fig. S2). In early experiments on weakly responding constructs,
we measured responses to much higher concentrations (up to
10mM).We extrapolated to responses at 1 µM nicotine, based on
the EC50, on the maximal ΔF (ΔFmax) and the observed Hill co-
efﬁcient of ∼1. We used automated liquid-handling devices at
several stages of mutagenesis and quantiﬁcation.
Measurements on puriﬁed iNicSnFRs
Biosensors selected for further studywere puriﬁed with the His6
sequence (Fig. S1). Proteins were puriﬁed by Ni-NTA afﬁnity
chromatography as described (Marvin et al., 2013), using PBS,
pH 7.4, and elution in an imidazole gradient (10–200 mM).
Proteins were concentrated by centrifugation through a 10- or
30-kD cutoff column and by dialysis against PBS. The dialyzed
protein was quantiﬁed, and 50 or (preferably) 100 nMwas used
in dose–response studies to characterize responses to various
ligands.
We conducted isothermal titration calorimetry experi-
ments with a Malvern Microcal iTC200 instrument. Puriﬁed
iNicSnFR3a (100 µM) was titrated with 1 mM nicotine in PBS at
25°C. Analyses used the Origin software bundled with that
instrument.
Proteins puriﬁed by size-exclusion chromatography were
subjected to high-throughput crystallization trials in the pres-
ence of nicotine. Crystals were grown with hanging drop vapor
diffusion at room temperature. Promising crystals of iNicSnFR1
were obtained with 15 mg/ml protein, 6 mM nicotine, 50 mM
MgCl2, 10 mM HEPES, pH 7.5, and 30% vol/vol polyethylene
glycol monomethyl ether 550. The diffraction datasets were
collected at Stanford Synchrotron Radiation Laboratory. The
data were reduced using Mosﬂm (Powell et al., 2017) and Scala
(Evans, 2011). The structure was solved using the CCP4 software
suite (Evans, 2011) to carry out molecular replacement using a
solved unliganded, open structure of an earlier version of
iAChSnFR construct (Borden et al., in preparation). The struc-
ture was iteratively rebuilt using Coot (Emsley et al., 2010) and
reﬁned using PHENIX. The maximum resolution was 2.4 A˚.
After reﬁnement (Table S1), the electron density for the ligand
was incompletely resolved; therefore the molecular docking
program SwissDock was used to study protein–ligand interac-
tions (Fig. 2 B) and to design further SSM libraries. After we
obtained the modeled-liganded, partially closed structure of
Fig. 2 B, we concentrated on mutating the residues noted; this
structural information accelerated progress toward the criterion
responses of ΔF/F0 = 0.3 at [nicotine] = 1 µM.
Spectrally resolved ﬂuorescence measurements of pH de-
pendence (Fig. 3, A–C) were conducted with an ISS (Champaign)
K2 ﬂuorometer running under MS-DOS. Excitation and emis-
sion bandwidths were 2 nm. Data were exported as ASCII ﬁles.
Dose–response relations for ligands were conducted with the
M1000 (Fig. 2 C) or Spark 10M (Fig. 3, D–H; and Fig. 9 A) plate
reader. For excitation wavelength (λex) of 400 nm, an ideal
emission ﬁlter would have been centered at ∼500 nm; but none
was available, so wemeasured the∼2-fold lower emissionwith a
ﬁlter centered at an emission wavelength (λem) of 535 nm.
Stopped-ﬂow experiments were conducted on an Applied
Photophysics SX-18MV instrument at 25°C. Equal volumes of
iNicSnFR3a solution (100 nM) and ligand solution in PBS were
mixed, yielding the ﬁnal nicotine and varenicline concentrations
given in Fig. 2 D and Fig. 9 B, respectively. The samples were
excited at 470 nm via a monochromator (9.3 nm slit width), and
the emission was collected at 520 nm using a 10-nm band-pass
ﬁlter. Waveforms were ﬁtted to single exponential waveforms,
using Applied Photophysics software.
Expression in mammalian cells
We constructed two variants of the iNicSnFR biosensors for
expression in mammalian cells. The constructs were cloned into
vectors designed for expression either on the PM (iNicSnFR_PM)
or in the ER (iNicSnFR_ER). For iNicSnFR3a_PM and
iNicSnFR3b_PM, we cloned the bacterial constructs into
pCMV(MinDis), a variant of pDisplay (Invitrogen) lacking the
hemagglutinin tag (Marvin et al., 2013). To generate iN-
icSnFR3a_ER and iNicSnFR3b_ER, we replaced the 14 C-terminal
amino acids (QVDEQKLISEEDLN, including the Myc tag; Fig. S1,
ﬁnal line) with an ER-retention motif, QTAEKDEL.
We conducted cDNA transfection experiments on iNiCSnFR3a_PM
and iNicSnFR3a_ER expressed in HeLa cells, in SH-SY5Y cell,
in HEK293 cells, and in N2a cells. All cell lines were purchased
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from ATCC and cultured according to ATCC protocols.
Chemical transfection was achieved by combining 0.5 or 1 µg
of plasmid with 1 µl of Lipofectamine 2000 (1 mg/ml; In-
vitrogen) in 500 µl OptiMEM (Gibco), incubating at room
temperature for 30 min, and adding to dishes with fresh
OptiMEM. Cells were incubated in the transfection medium
for 24 h and then in growth media for ∼24 h before imaging.
For experiments on cultured mouse hippocampal neurons,
an effective expression procedure used adeno-associated
viral (AAV2) constructs. As stated in Results, iNicSnFR3a and
iNicSnFR3b gave identical ΔF in solution experiments and in
transfection experiments. After we obtained preliminary data
with AAV2/1 constructs for iNiCSnFR3bwith a synapsin promoter
(in this paper, usually abbreviated AAV2_iNicSnFR3b_PM and
AAV2_iNicSnFR3b_ER); we therefore judged that it was an
unnecessary expense to generate the analogous iNicSnFR3a
AAV constructs. The cells were grown on circular coverslips
(1 cm diameter) glued to the bottom of 35-mm culture dishes
(MatTek).
GFP immunoblot quantitation of biosensor levels
Transfected HeLa cells were lysed using 50 mM NaCl, 50 mM
NaH2PO4, 2 mM EDTA, 2 mM EGTA, and 2% Triton X-100, pH
7.4 with 40 strokes of a disposable polypropylene pestle and
incubated for 3 h at 4°C with agitation to solubilize membrane-
bound proteins. The membrane fraction was pelleted via cen-
trifugation (21,130 g for 10 min at 4°C) and the supernatant
containing the protein fraction was isolated. Isolated proteins
were incubated at 95°C for 5 min in 1× Laemmli sample buffer
and 355 nM β-mercaptoethanol (BioRad). The pH of each sample
was adjusted with 1 M Tris base and then alkylated using
100 mM iodoacetamide at 20–25°C for 1 h in the dark. Proteins
were separated by SDS-PAGE using a 6–18% bis-Tris gel and
transferred to Immun-Blot low ﬂuorescence polyvinylidene
Figure 2. The genetically encoded family of
biosensors for nicotinic drugs, iNicSnFRs. (A)
Cartoon of the x-ray crystallographic structure of
iNicSnFR1, crystallized in the presence of nico-
tine. The structure is available as PDB ﬁle 6EFR.
The iNiCSnFR family are fusion proteins. A su-
perfolder cpGFP (shown in green) has been in-
serted into the coding sequence of OpuBC, a
choline/betaine PBP from T. spX513. The linker
sequences (shown in dark blue; see Fig. S1) were
selected for optimal ΔF/F. One poorly resolved
linker residue, Pro323, is shown as a dashed
backbone. The engineered OpuBC is shown in
cyan, except that the backbone residues near the
incompletely resolved nicotine ligand are shown
in gray. The nicotine-binding site lies between
the two lobes of the PBP; these move relative to
each other. (B) To generate later iNicSnFRs, the
binding site of OpuBC was further engineered by
mutagenesis for acceptable sensitivity to nico-
tine. ∼12,000 mutants were screened during the
design of iNicSnFR3a and iNicSnFR3b. The image
shows redesign of the nicotine-binding site of
iNicSnFR1, naming the additional mutations
present in iNicSnFR3a and iNicSnFR3b. Portions
of the cartoon shown in gray are identical to the
gray regions of OpuBC in A. The α-carbon atoms
remain at the positions in the x-ray crystallo-
graphic data (PDB ﬁle 6EFR), and the conformers
of the mutated side chains were selected based
on the best-ﬁt rotamer using University of Cali-
fornia, San Francisco (San Francisco, CA) Chi-
mera software. The pyrrolidine group of nicotine
is at left, seen edge-on; the pyridine group is at
right, seen from an acute angle. Also shown is
Y357, which remains wild type in all iAChSnFR
and iNicSnFR constructs (Fig. S1). The Y357A
mutation renders all iNicSnFR and iAChSnFR
constructs insensitive to the ligand. Also shown
is F391, which remains unchanged in all iNicSnFR
and iAChSnFR constructs, but differs from the
glutamate in OpuBC. (C) Dose–response relations for puriﬁed iNicSnFR3a. Data were ﬁtted to a single Hill equation with an assumed Hill coefﬁcient of 1. Data
are mean ± SEM (n ≤ 3). (D) Stopped-ﬂow analysis. The rate constant for ﬂuorescence decay, koff, was measured most consistently by extrapolation of the kon
value to zero [nicotine] (koff-ext). The ratio, koff-ext/kon, gives an equilibrium-binding constant Kd = 29 µM. The blue symbols and label showmeasurements of koff
in experiments that diluted an iNicSnFR3a-nicotine solution by 25-fold to [nicotine] values < 1 µM (koff-dil). (E) Isothermal titration calorimetry for nicotine. The
data yield an equilibrium-binding constant Kd = 10 ± 2.5 µM, and a stoichiometry of 0.65 ± 0.03 moles of nicotine per mole of protein.
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ﬂuoride membranes (BioRad). Membranes were blocked using
Odyssey Tris-buffered saline (TBS; Li-Cor) for 1 h at room
temperature and then incubated with mouse anti-GFP anti-
bodies (2955S; Cell Signaling), diluted 1:1,000 in Odyssey TBS-
blocking buffer, supplemented with 0.1% Tween-20 (“antibody
buffer”) overnight at 4°C. After washing, the membrane was
incubated with anti-mouse secondary antibodies (925-32212;
Li-Cor) diluted 1:10,000 in antibody buffer. The blot was
washed and visualized using an Odyssey scanner (Li-Cor).
Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibodies (1:1,000 in antibody buffer; Ab9483; Abcam) were
used as a loading control. GAPDH immunoreactivity was
visualized with anti-goat secondary antibodies (1:10,000; 926-
68074; Li-Cor). Anti-GAPDH primary and secondary anti-
bodies were added concurrently with anti-GFP primary and
secondary antibodies. To quantify biosensor levels, a standard
curve of puriﬁed soluble iNicSnFR3b protein (0.23, 1.15,
and 5.76 ng protein, in duplicate) was used in each blot. Data
were analyzed using Odyssey application software (version
3.0; Li-Cor).
Preparation and transduction of hippocampal neurons
A pregnant mouse was euthanized at embryonic day 16. The
pups were removed from the uterine sac and decapitated before
dissection. The hippocampi from several pups were combined
and digested in 50 units of papain for 15 min. After DNase
treatment, cells were triturated in Hanks balanced salt solution
(HBSS; ThermoFisher; GIBCO) with 5% equine serum and spun
down through a 4% BSA solution. The pellet was resuspended
in plating medium, and the cells were plated onto glass bottom
Figure 3. The pH dependence of puriﬁed
iNicSnFR3a in solution, over the range pH
5.5–9.0, at 25°C. Measurements were per-
formed in 3× PBS, adjusted to nominal pH within
0.1 pH unit. (A–C) Measurements in a spectro-
ﬂuorometer (see Materials and methods).
100 nM protein. Fluorescence is measured in the
absence of ligand and termed F0. (A) Excitation
spectra at various pH values, measured at a λem
of 535 nm. (B) Emission spectrum at a λex of
400 nm. Note that F0 depends to only a limited
extent on the pH. (C) Emission spectrum at λex =
485 nm. Note the strong dependence on pH.
(D–H) Measurements in a 96-well plate reader,
bandwidth 20 nm for excitation and 25 nm for
emission; 50 nM protein, 25°C. (D) Data analo-
gous to those of B and C. pH dependence of F0,
with λex = 400 nm (open symbols) or 485 nm
(closed symbols). Arbitrary units on the y axis
(log scale; 30–3,000 arbitrary units; a.u.) differ
from those taken with the instrument of A–C.
Values for SEM are smaller than the size of the
symbols. (E and F) Fluorescence dose–response
relations for nicotine (E) and for N’MeNic (F).
Excitation at 485 nm, at varying pH between 7.5
and 9.0. The data have been ﬁtted to a single
Hill equation, with parameters given in the leg-
end. Error bars give SEM. Uncertainties for the
ΔFmax/F0 and EC50 values are <10%, and for the
Hill coefﬁcient (nH) value are <0.2. (G) Summary
of E and F to show both the unliganded ﬂuoresce
(F0) and maximal ﬂuorescence (F0 + ΔFmax) in
the pH range measured. (H) Exemplar dose–
response relations from excitation at 400 nm, at
pH 6.0. As expected (Barnett et al., 2017), nico-
tine produces a decrease in ﬂuorescence inten-
sity at 535 nm. The data have been ﬁtted to a
single Hill equation, with parameters given in
the legend. Error bars give SEM. (I) Comparison
of EC50 values for nicotine (squares) versus
N’MeNic (circles). Data from experiments like
those in B and C. Excitation at 400 and 485 nm
are given by the open and closed symbols, re-
spectively. Data were included if they were well
ﬁtted by a Hill coefﬁcient between 0.75 and 1.2,
if the observed ΔF at 1,000 µM ligand reached
>85% of the ﬁtted ΔFmax, and if the curve-ﬁtting
algorithm provided error bounds of EC50 < 10%.
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35-mm imaging dishes (MatTek) coated with poly-D-lysine,
poly-L-ornithine, and laminin. After 1 h, the cells were ﬂooded
with 3 ml of culture medium, and half of the culture medium
was changed every 3 d. At 3 d in vitro, the cells were infected
with AAV2_iNicSnFR3b_PM or AAV2_iNicSnFR3b_ER at a
multiplicity of infection of 100,000 or 50,000, respectively.
Expression in dopaminergic neurons differentiated from
human induced pluripotent stem cells (iPSCs)
Fujiﬁlm CDI (formerly named Cellular Dynamics International;
CDI) furnished iCell DopaNeurons. These are human dopamin-
ergic neurons differentiated from iPSCs. The supplier has
measured that 89% of the cells are positive for tyrosine hy-
droxylase (TH) by ﬂuorescence-activated cell sorting. The iCell
DopaNeurons were maintained in 95% BrainPhys Neuronal
medium (StemCell Technologies), 2% iCell Neural Supplement B
(CDI), 1% iCell Nervous System Supplement (CDI), 0.1% of 1 mg/ml
laminin (Sigma), and 1% N-2 Supplement 100× (ThermoFisher)
and supplemented with penicillin and streptomycin. iCell
DopaNeurons were maintained on dishes for 17–24 d before
imaging. Glass bottoms of the 35-mm imaging dishes (MatTek)
were coated with ∼0.07% poly(ethyleneimine) solution and
incubated at 37°C for 1 h. Dishes were rinsed with PBS, then
rinsed with water and air dried overnight. Glass bottoms were
then coated with 80 µg/ml laminin solution for 30 min at 37°C
before cells were plated. We conﬁrmed that ≥40% of the cells
stained for TH by immunocytochemistry using a previously
described assay (Srinivasan et al., 2016).
iCell DopaNeurons were transfected after either 13 or 21 d in
culture using the Viafect kit (E4981; Promega) at 4:1 transfection
reagent (µl) to DNA (μg) ratio. The transfection mixture was
prepared in 100 µl OptiMEM (ThermoFisher), containing 4 μL
of Viafect transfection reagent and 1 μg of either iNicSnFr3a_ER
or iNicSnFr3b_PM cDNA. The mixture was incubated for
10–15 min and then added directly to fresh maintenance me-
dium in the culture dish. Transfection medium was removed
after 24 h, and cells were incubated for 48–72 h further before
imaging.
iCell DopaNeurons were transduced with AAV2_i-
NicSnFr3b_ER virus particles after 7 d in culture. 1 µl of the stock
(2 × 1012 genome copies/ml) was mixed with 100 µl of mainte-
nance medium, and then the mixture was added to 2 ml of
maintenance medium in the culture dish. Cells were studied
after 24 d in culture.
Time-resolved ﬂuorescence measurements in live
mammalian cells
Experiments have been conducted at room temperature with
four inverted microscope systems; each produced useful ﬂuo-
rescence increases when nicotine or varenicline was perfused
into the chamber. Early experiments used a Zeiss 510 spectrally
resolved laser-scanning confocal microscope, previously used
for other biosensors that use cpGFP moieties. This group in-
cludes the GCaMP sensors and iGluSnFR (Marvin et al., 2013).
We ﬁnd that signals with the iNiCSnFR constructs have
brightness and dynamic range similar to those of the previous
cpGFP-based biosensors.
Most datasets were taken on an Olympus IX-81 microscope,
in wide-ﬁeld epiﬂuorescence mode. Images were acquired at 3–4
fps with a back-illuminated EM charge-coupled device camera
(iXon DU-897; Andor Technology; Pantoja et al., 2009), con-
trolled by Andor IQ2 software. Initial experiments used excita-
tion by the 488-nm line of an argon laser (IMA101040ALS;
Melles Griot; Richards et al., 2011); however, this produced
speckles and also excessive bleaching when the iNicSnFR was
activated by ligands (Fig. S3). Therefore, we installed a consid-
erably weaker incoherent light source: a light-emitting diode
(LED). Although a peak at ∼485 nm would have been optimal,
the closest available LED had peak emission at 470 nm (LZ1-
10DB00; Led Engin). We used a 40-nm band-pass ﬁlter, centered
at 470 nm (ET 470/40X; Chroma Technology), at currents of
40–800 mA. The epiﬂuorescence cube was previously described
(Srinivasan et al., 2011). We obtained useful signals with 20×
(numerical aperture [NA] 0.4), 40× (NA 1.0; oil), 63×, and 100×
(NA 1.45) lenses. The 40× lens proved most convenient for
imaging several adjacent cells and was relatively insensitive to
modest drift of the focus. For HeLa cells, the PM-directed con-
structs were measured with a region of interest (ROI) that in-
cluded only the cell periphery.
Solutions were delivered from elevated reservoirs by gravity
ﬂow, through solenoid valves (Automate Scientiﬁc), then
through tubing fed into a manifold at a rate of 1–2 ml/min. Ex-
periments were performed with HBSS buffer, except that iPSC-
derived neurons were studied in PBS plus D-glucose (5.56 mM),
MgCl2 (0.49 mM), MgSO4 (0.4 mM), KCl (5.33 mM), and CaCl2
(1.26 mM). The most robust datasets were taken with gas-
impermeable ﬂuorinated ethylene propylene-lined Versilon
tubing. This minimized loss of CO2, which in turn would pro-
duce transient pH increases that artifactually increased bio-
sensor ﬂuorescence in the absence of ligand (Fig. S5). Culture
dishes were placed on a Warner Instruments SA-TS100 adapter
that supported a DH-40i perfusion ring. With this arrangement,
the stainless steel tubes for the inlet and aspiration were sepa-
rated by 5 mm. Videos of dye solutions showed that local solu-
tion changes proceeded with a time constant of <1 s (California
Institute of Technology “Katz” station). As usual in ﬂuorescence
imaging experiments, we excluded data from the brightest cells,
because these may have ﬂuorescent impurities or aggregates
that produce a rapidly bleaching baseline (an example is the
black trace in Fig. S5). Data analysis procedures included sub-
traction of blank (extracellular) areas and corrections for base-
line drifts.
Experiments with micro-iontophoretic nicotine application
(Fig. 7) used the following optical and electrophysiological in-
struments. A Nikon Diaphot 300 wide-ﬁeld microscope was
equipped with an Hg arc lamp (100 W), a 40× (NA 0.33) ob-
jective lens, and a ﬂuorescein/GFP epiﬂuorescence cube. Images
were acquired with a Hamamatsu Orca 03G camera, controlled
by Hamamatsu software. Iontophoretic pipettes were ﬁlled with
1 M nicotine HCl, had resistance of ∼50 MΩ and were mounted
on a micromanipulator. Current was supplied by an Axon In-
struments Geneclamp 500, commanded by Axon Instruments
pCLAMP software (California Institute of Technology “Erlanger”
station).
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Structured illumination microscopy and confocal
ﬂuorescence images
Cells were cotransfected with cDNA for DsRed2-ER (Srinivasan
et al., 2012) and with iNicSnFR3a_ER or iNicSnFR3a_PM (0.5 µg
of each construct combined with 1 µl of Lipofectamine 2000 was
added to the cells in OptiMEM and incubated for 24 h, followed
by incubation in growth media for ∼24 h). The image in Fig. 4 C1
was acquired as Z stacks with a Zeiss ELYRA S.1 microscope,
equipped with a 63× NA 1.4 objective lens. GFP illumination was
at 488 nm, observed through a 495–550 nm band-pass + 750 nm
long-pass ﬁlter. DsRed2-ER was illuminated at 561 nm and ob-
served through a 570–620 band-pass + 750 long-pass ﬁlter. The
structured illumination grating was rotated ﬁve times and
processed using Zeiss ZEN software to produce the ﬁnal image.
The image in Fig. 4 C2 was acquired with a Zeiss LSM
710 laser-scanning confocal microscope, equipped with a 63× NA
1.4 objective lens. Neither microscope has a perfusion system;
solutions were changed with a pipette. Nicotine (15 µM nicotine
in HBSS) was used to wash and replace the growth medium in
the dishes before imaging.
Reagents
(—)–Nicotine salts or free base (>98% purity) were obtained
from several suppliers, with no detectable difference in prop-
erties. Samples of N’-methylnicotinium (N’MeNic; Fig. 1 C) were
obtained from two sources, with no detectable difference in
properties. A sample was synthesized by M.R. Post (California
Institute of Technology), as described (Post et al., 2017), and
puriﬁed by P.S. Lee (Janelia Research Campus). Other samples
were purchased from Toronto Research ((S)-1’-methylnicotinium
Iodide; M323280), and purity was veriﬁed byNMR by D.P.Walton
(California Institute of Technology).
Pharmacokinetic and pharmacodynamic simulations
Simulations of nicotine and varenicline in human subjects were
constructed and run in Matlab (2017a and later releases) using
Figure 4. Protein levels and subcellular imag-
ing of iNicSnFR3a_PM and iNicSnFR3a_ER in
HeLa cells. (A) Typical immunoblots with anti-GFP
immunoreactivity to lysates (1 µg protein) from
HeLa cells transfected with either iNicSnFR3a_PM
(top) or iNicSnFR3a_ER (bottom). In each panel,
the leftmost lane is the 75-kD molecular weight
marker (MWM). The two middle lanes are du-
plicate samples of puriﬁed, diluted iNicSnFR3b
(∼61 kD). The two rightmost lands are duplicate
samples from the transfected cells. Bands for
iNicSnFR3a_PM appear at ∼68 kD (slightly be-
low the MWM), and bands for iNicSnFR3a_ER
appear at ∼61 kD (markedly below the MWM
and comparable with puriﬁed biosensor), con-
ﬁrming the predicted size difference of 7 kD
between the two constructs. (B1) Absolute
quantitation of iNicSnFR3a expression, based
on GFP immunoblots, from ﬁve paired trans-
fections, analyzed 7–23 h after transfection.
Data are mean ± SEM (two duplicate lanes
loaded with 1 µg protein per blot; one blot per
transfection). Signiﬁcance was determined us-
ing an unpaired Student’s t test. *, P ≤ 0.05; n.s.,
not signiﬁcant. (B2) Ratio of iNicSnFR3a_PM to
iNicSnFR3a_ER levels, within each set of
transfections. The ratio varied from 0.40 to 0.95
with an average of 0.56 ± 0.10. The bar gives
SEM. (C) Typical ﬂuorescence microscopy im-
ages from cells cotransfected with iNicSnFR3a
and with DsRed2-ER (red channel) and exposed
to nicotine (15 µM). (C1) iNicSnFR3a_ER (green
channel) and DsRed2-ER (red channel) and
merged image. Structured illumination micros-
copy. (C2) iNicSnFR3a_PM (only the green
channel is shown). Confocal microscopy.
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the SimBiology App. The detailed parameters of the simulation
are given in Table S2. The code is available in SimBiology format
(.sbproj, which presents the formatting of the diagrams in Fig. 8 A
and Fig. 10 A, and in Systems Biology Markup Language [.xml].
See the ZIP ﬁle contained in the Supplemental material).
Data analysis software
Image video ﬁles, spectral data, and dose–response data were
analyzed further and presented with general purpose software.
These programs include ImageJ, Excel (Microsoft), and Origin
(OriginLab).
Online supplemental material
Online supplementary information includes text information
that amine-containing buffers produce anomalous results and
that acidic vesicles are candidates for the “sequestered com-
partment;” Table S1 shows steps in structure and reﬁnement
of iNicSnFR1 crystallized with nicotine; Table S2 shows pa-
rameters for nicotine and varenicline Matlab/SimBiology mod-
els; Fig. S1 shows sequences of PBPs and constructs described in
this paper and/or studied in preliminary experiments; Fig. S2
shows directed evolution of the iNicSnFR family; Fig. S3
shows photoswitching noticeable at high [nicotine] with focused
laser illumination; Fig. S4 shows responses to nicotine with
iNicSnFR_ER in SH-SY5Y cells and HEK293 cells; Fig. S5 shows
human iPSCs, differentiated to dopaminergic neurons, trans-
duced with AAV_iNicSnFR3b_ER; and Fig. S6 shows varenicline
at iNicSnFR3a expressed in HeLa cells. Additional online sup-
plementary information includes a ZIP ﬁle containing Matlab
SimBiology models for nicotine and varenicline in .sproj and
Systems Biology Markup Language (.xml) format. Additional
online supplementary ﬁles include a guide to the online videos,
of which there are nine.
Results
Development and characterization of iNicSnFRs
We identiﬁed and optimized iNicSnFRs in parallel with the re-
search program that produced the genetically encoded ACh
biosensor molecule, iAChSnFR (Borden et al., in preparation).
We had two goals for the optimized iNicSnFRs. (1) We sought
≥30% increase in ﬂuorescence (ΔF/F0 ≥ 0.3) at [nicotine] = 1 µM,
a concentration thought to lie at the upper end of the range of
the peak [nicotine] in the plasma and brain of a smoker. (2) We
sought to achieve this response with a time constant <1 s.
Many bacterial and archaeal species use the quaternary
amines choline, glycine betaine, and proline betaine as osmo-
lytes or energy sources. PBPs (also called substrate-binding
proteins; SBPs) from some of these species bind these ligands,
then present the ligands to transporters in the inner membrane.
Structural studies of ligands bound to PBPs show a feature ﬁrst
noted by Schiefner et al. (2004a): a “box” of four aromatic side
chains that participate in cation-π interaction(s) with the qua-
ternary amine. This feature was previously noted for nAChRs
(Zhong et al., 1998; Brejc et al., 2001; Morales-Perez et al., 2016).
Furthermore, a cation-π box participates prominently in bind-
ing to other Cys-loop and G protein–coupled receptors (GPCRs)
for other primary and secondary amine ligands including
serotonin, GABA, glycine, and many drugs that mimic those
transmitters (Van Arnam et al., 2013). We hypothesized that
choline- and/or betaine-binding PBPs could be mutated by ex-
perimenters to bind ACh, nicotine, and perhaps other alkaloid
(nitrogen containing, weakly basic) drugs. PBPs undergo sub-
stantial, well-characterized ligand-induced conformational
changes upon binding their target ligand. In SnFRs, cpGFP is
inserted into a PBP in such a way that this conformational
change is allosterically transduced into rearrangements of the
chromophore environment, leading to changes in ﬂuorescence
intensity, lifetime, etc. (Marvin et al., 2013). We reasoned that
this strategy would work similarly well with PBPs mutated to
bind exogenous molecules, so as to enable families of genetically
encoded ﬂuorescent biosensors for drugs (iDrugSnFRs).
In preliminary experiments, we synthesized the genes and
expressed in bacteria PBPs of structural Class F (Berntsson et al.,
2010), thought to bind choline and/or betaine. Studies included
ChoX from Sinorhizobium meliloti (Oswald et al., 2008), ProX
from Archaeoglobus fulgidus (Schiefner et al., 2004b), OpuAC
from Lactococcus lactis (Wolters et al., 2010), OpuCC from Bacillus
subtilis (Du et al., 2011), and OpuBC from Bacillus subtilis
(Pittelkow et al., 2011). An OpuBC homologue (possibly a ProX
homologue) from the hyperthermophilic bacterial species
Thermoanaerobacter sp X513 appears in genomic databases, but
was not previously characterized. We ﬁrst performed isother-
mal titration calorimetry to detect any binding with the puriﬁed
proteins. This paper presents experiments with the most
promising PBP, the T. sp X513 OpuBC homologue; we found that
betaine, choline, and ACh bind to this protein. We coupled it to
cpGFP and optimized its sensitivity to nicotine, as described in
Materials and methods and in Fig. 1 and Fig. S2.
We obtained an x-ray crystallographic structure of an early
iNicSnFR, termed iNicSnFR1, in the presence of nicotine at 2.4 A˚
resolution (Fig. 2 A and Table S1, deposited as PDB ﬁle 6EFR).
This construct has an apparent nicotine EC50 of 250 µM. This is,
to date, the only iNicSnFR structure we have obtained in a li-
ganded, closed (or partially closed) conformation. The structure,
in common with several other OpuBC-related structures dis-
cussed above, reveals the ligand at the interface between two
domains of the PBP moiety. Four aromatic side chains, con-
tributed by both lobes, surround the pyrrolidine nitrogen. This
resembles the “aromatic box” found in many PBPs that bind
quaternary amines, as well as in nAChRs.We also obtained x-ray
crystallographic structures of several other constructs in the
iNicSnFR series; but in these, the upper domain of the PBP was
ﬂexed away from its position in Fig. 2 A, and there was no ligand
present. Fig. 2 B presents our model of the ligand–protein in-
teraction site of iNicSnFR3a and iNicSnFR3b.
During the development of iAChSnFR, for additional assur-
ance that the ligand binds approximately as predicted in Fig. 2 B,
we mutated several of the putative cation-π residues annotated
as α through η noted in Fig. S1. The most dramatic elimination of
sensitivity occurred at the γ aromatic residue, with the Y357A
mutation. In Fig. 5 E, presented below, we show that incorpo-
rating the equivalent mutation into an iNicSnFR also eliminates
nicotine sensitivity.
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We used excitation near the absorption peak at 485 nm, and
we made emission measurements at wavelengths >510 nm.
Fig. 2 C shows dose–response relations for ΔF induced at
iNicSnFR3a by three nicotinic agonists: nicotine, ACh, choline,
and cotinine. The EC50 for choline is more than fourfold greater
than for nicotine, showing a greater-than-desired sensitivity,
but higher than the usual value for choline in brain (∼10 µM;
Klein et al., 1992). The near-zero ΔF values for cotinine are too
small for systematic study. The iNicSnFR3a and iNicSnFR3b
proteins differ by one amino acid substitution at codon 11 (Asn
vs. Glu, respectively; Fig. S1) and have no detectable photo-
physical differences.
The stopped-ﬂow data (Fig. 2 D) show that the ﬂuorescence
increase reached steady-state with time constants extrapolating
to a value of koff-ext = 2.0 s−1 at the lowest [nicotine]. This sat-
isﬁed the criterion that the kinetics should be substantially
complete within 1 s. In other experiments that diluted premixed
solutions of 200 nM iNicSnFR3a plus nicotine into PBS, we
measured modestly higher values of koff-dil = 3.3 ± 0.3 s−1.
However, we consider koff-dil measurements less satisfactory
because the resulting iNicSnFR3a concentrations were just
8 nM, producing small and noisy signals. The isothermal titra-
tion calorimetry data (Fig. 2 E) also show that nicotine binds to
iNicSnFR3a (Kd = 10 ± 2.5 µM). Thus, all the available data in-
dicate a noncooperative interaction between iNicSnFR3a and
nicotine, with a Kd between 10 and 30 µM, that is complete
within ∼1 s.
pH dependence of an iNicSnFR
We based additional photophysical studies on previous data with
the GCaMP family. In the inactive conformation of cpGFP, the
ﬂuorophore has a pKa of 8–9. At neutral pH, the ﬂuorophore is
almost fully protonated, decreasing the absorption in the band
centered at λex∼485 nm (Barnett et al., 2017). In the active form,
the pKa is ∼7, so that some of the ﬂuorophore molecules are
deprotonated. This allows absorption and ﬂuorescence (Barnett
et al., 2017). Our pH studies have the additional feature that
nicotine itself is a weak base (Fig. 1, A and B), as are varenicline
and many other neural drugs. One expects both the pH depen-
dence of the biosensor, and that of the ligand, to affect meas-
urements with iNicSnFRs. We also sought to determine whether
the charged or the uncharged form of nicotine binds to the
iNicSnFRs.
We investigated the pH dependence of both ligand-
independent and ligand-induced ﬂuorescence (F0 and ΔF, re-
spectively, Fig. 3). Throughout the pH range from 5.5 to 9.0,
excitation at λex = 400 nm produces detectable F0 at an λem of
535 nm, and this is nearly independent of pH (Fig. 3, A and B).
This agrees with previous data on cpGFP-based biosensors
(Barnett et al., 2017). The F0 values for λex = 485 nm show the
expected, contrasting strong pH dependence (Barnett et al.,
2017): F0 is approximately inversely proportional to [H+]
(Fig. 3 C).
We determined the ΔF dose–response relations of iNicSnFR3a
using excitation at λex = either 400 or 485 nm. At basic pH, we
found the most reliable signals at λex= 485 nm, where nicotine
induces increased ﬂuorescence (ΔF > 0; Fig. 3 E). The ΔFmax
decreases with increasing pH. Thus, ΔFmax/F0 at pH 7.5 is 14.5;
but at pH 9.0, ΔFmax/F0 is only 3.5. This analysis is summarized
by plotting both F0 and F0 + ΔFmax in the measured range
(Fig. 3 G). The pH dependence of the F0 measurements is con-
sistent with those measured more precisely in a spectroﬂuo-
rometer (Fig. 3 C). The pH dependence of the fully saturated
biosensor (F0 + ΔFmax) resembles that for the fully saturated
GCaMP sensors (Barnett et al., 2017), reaching a plateau under
basic conditions; however, the apparent pKa of iNicSnFR3a may
be shifted to the right by ∼0.5 pH units from that for GCaMP6m
(Barnett et al., 2017).
At acidic conditions for λex = 485 nm, nicotine evokes little or
no ΔF; we therefore excited at λex = 400 nm and measured the
nicotine-induced ﬂuorescence decrease (ΔF < 0; Fig. 3 H). At pH
= 7.5 and 8.0, where the two measurement modes both have
adequate signals, the two modes yield good agreement in EC50
values (Fig. 3 I), consistent with the idea that the two modes are
measuring the same nicotine-iNicSnFR binding. Nicotine ex-
hibits a ∼20-fold decrease in EC50 as the pH is increased from
6.0 to 9.0 (Fig. 3 I). Both this pH dependence of the response to
nicotine and the large pH dependence of F0 are complicating
factors in our live-cell experiments.
A special environment in the iNicSnFR3-binding site
The nicotine derivative N’MeNic (Fig. 1 C) has a quaternary
ammonium moiety at the pyrrolidine (N’) nitrogen. Like
nAChRs (Beene et al., 2002; Post et al., 2017), iNicSnFR3 re-
sponds robustly to N’MeNic. Comparing N’MeNic-induced with
nicotine-induced ΔF over a pH range is expected to reveal fur-
ther mechanistic details about the ligand–protein interaction,
independent of the pH dependence of other regions and/or
transitions of the biosensor protein.We consider that systematic
errors render the data most reliable for λex = 400 nm at pH ≤ 7.5,
and for λex = 485 nm at pH ≥ 7.5. Fig. 3 (E–G) show that iN-
iCSnFR3a responds similarly to nicotine and to N’MeNic, with
respect both to EC50 and to ΔFmax/F0, at basic pH. Fig. 3 G shows
that the fully liganded state has a similar pH dependence
whether the ligand is nicotine or N’MeNic. We found a similar
trend under acidic conditions. Fig. 3 I shows that, over almost
the entire measurable range from pH 6.0 to 9.0, the EC50 value
for nicotine is 1.25- to 2-fold higher than that for N’MeNic. The
modestly higher sensitivity to N’MeNic is not surprising, con-
sidering that the natural ligand of OpuBC is either choline or
betaine, both quaternary compounds. Many nicotine-binding
sites, such as those in AChBP and nicotinic receptors, tolerate
the differences in charge density among protonated secondary
amines (such as cytisine and varenicline), protonated tertiary
amines (such as nicotine and ABT-418), and quaternary amines
(such as choline and N’MeNic; Daly, 2005; Van Arnam and
Dougherty, 2014).
How do we explain that the EC50 for nicotine remains a small
multiple of the N’MeNic EC50 over nearly the entire measurable
pH range, even though the concentration of protonated nicotine
in free solution decreases for pH values above its pKa (7.5–8)? In
a straightforward explanation, the binding site of iNicSnFR3,
probably including a cation-π box, stabilizes diffuse positive
charges such as those in quaternary amines and in protonated
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tertiary amines. Previous pH dependence studies of nAChRs
show this phenomenon (Petersson et al., 2002). Regardless of
the underlying mechanism, the data suggest that the pH de-
pendence of the cpGFP moiety exerts a stronger effect than the
pH dependence of the weakly basic ligand, nicotine.
Studies with nicotine in live cells
iNicSnFR3a_PM and iNiCSnFR3a_ER in HeLa cells
We conducted many of our optical and biochemical experiments
in HeLa cells, which have a relatively large, ﬂat appearance
and prominent ER. Fig. 4 (A and B) shows protein expression
of iNicSnFR3a_PM and iNiCSnFR3a_ER after transfection in
HeLa cells. We performed immunoblotting using an anti-GFP
antibody. Observed GFP immunoreactivity for proteins from
iNicSnFR3a_PM- and iNiCSnFR3a_ER-transfected cells appears
near the predicted values of ∼68 and ∼61 kD, respectively. Im-
portantly, immunoblots demonstrated that the PM targeted
biosensor is larger than the ER targeted biosensor, accounted for
by the addition of the PM targeting sequence. We found no other
bands with GFP immunoreactivity. In experiments conducted at
7–23 h post-transfection, we found that iNicSnFR3a_PM pro-
duced lower levels of protein than iNicSnFR3a_ER (22 ± 6 nM/mg
protein compared with 43 ± 14 nM/mg protein, respectively).
This expression level difference was not signiﬁcant when
we averaged absolute protein levels across the entire dataset
(Fig. 4 B1), but was consistent and signiﬁcant when assessed
within each paired (same day) set of transfections (Fig. 4 B2).
No detectable dependence on the time since transfection
was observed.
We also imaged the transfected cells with higher-resolution
ﬂuorescence microscopy (Fig. 4 C). We cotransfected some
of these samples with DsRed2-ER to assess localization with the
ER. As expected from the included targeted sequences, the
iNiCSnFR3a_ER construct showed the expected ER structures
typical of HeLa cells, and also colocalized well with DsRed2-ER
(Fig. 4 C1). The iNiCSnFR3a_PM ﬂuorescence was most intense
at the periphery of the cell, as expected for a PM protein
(Fig. 4 C2).
Fig. 5 presents a typical time-resolved ﬂuorescence experiment,
∼24 h after transfection. For reasons reported in Section 1 above,
the time-resolved imaging experiments were performed with
illumination near the 485 nm absorption peak (see Materials
and methods). Images were gathered at 4 Hz while cells were
exposed to 20-s pulses of nicotine at 40-s intervals at fourfold
concentration increments between 0.25 and 256 µM. Nicotine-
induced ﬂuorescence increases are well resolved, even at
0.25 µM. We note good reproducibility among cells: the coef-
ﬁcient of variation of ΔF/F0 < 10% within an experiment.
Within a few seconds after the nicotine pulse begins in the
extracellular solution, nicotine-induced ﬂuorescence reaches
an approximate plateau and changes by <10% over the next 20 s
(the small increase in Fig. 5 was observed in only some ex-
periments). Within a few seconds after [nicotine] is stepped to
zero in the external solution, ΔF returns to zero. The temporal
resolution of these experiments is limited by the speed of
the solution change; we detected no difference between the
iNicSnFR3a_PM and iNicSnFR3a_ER waveforms.
Fig. 5 exempliﬁes an idiosyncrasy of the HeLa cell nicotine-
induced ﬂuorescence increases. The dose–response relation at
the higher [nicotine] shows less saturation than expected from
experiments on puriﬁed iNicSnFR3a (Fig. 2 C and Fig. 3 E). We
devoted little attention to this phenomenon, because [nicotine]
never exceeds ∼10 µM during smoking or vaping.
iNicSnFR3_ER detects only membrane-permeant molecules
A key goal for our experiments is to distinguish ER nicotine li-
gands from extracellular molecules. Therefore we compared
responses to nicotine itself versus two quaternary amines,
thought to be membrane-impermeant molecules: N’MeNic and
ACh (Fig. 5 E). In cells transfected with iNicSnFR3a_PM,
we found comparable ﬂuorescence increases among the three
ligands. In contrast, for cells transfected with iNicSnFR3a_ER,
only nicotine evoked ﬂuorescence increases. In solution,
iNicSnFR3a has comparable ΔF to nicotine, N’MeNic, and ACh
(Fig. 2 C and Fig. 3, E and F). Therefore it may be concluded that
iNicSnFR3a_ER samples only intracellular molecules. Given
the predominant ER localization of iNicSnFR3a_ER (Fig. 4 C1),
it may be concluded that this biosensor measures primarily
ligands in the ER. We provide, in the section “Studies with
varenicline in vitro and in live cells” of this paper, evidence that
iNicSnFR3a_ER responds strongly to varenicline, an additional
membrane-permeant ligand.
The data of Fig. 5, by themselves, cannot rule out the possi-
bility that iNicSnFR3a_PM samples some intracellular nicotine.
We argue against this possibility by noting the images of Fig. 4
C2, showing that iNicSnFR3a_PM ﬂuorescence occurs only on
the periphery of the cell. To investigate further, we conducted
nicotine exposure experiments on iNicSnFR3a_PM with a 100×
objective lens, and we chose ROIs including only the periphery.
We found that ΔF/F0 measurements had comparable values to
those of ROIs that include the entire cell (data not shown). One
objection to these “periphery-only” experiments is that some
iNicSnFR3a_PMmight remain within endosomes that cannot be
distinguished from the PM by light microscopy, as found for
some transporters (Chiu et al., 2002; Moss et al., 2009). How-
ever such compartments have luminal pH values ∼5.5, and in-
traluminal cpGFP would fail to ﬂuoresce. In summary, there is
good evidence that iNicSnFR3a_PM and iNicSnFR3a_ER mea-
sure the nicotine concentration in the extracellular solution and
in the ER, respectively.
Transfection of iNicSnFR3a_PM and iNicSnFR3a_ER into two
other human clonal cell types, SH-SY5Y (Fig. S4 A) and HEK293
(Fig. S4 B) produced similar ΔF values in response to nicotine
perfusion. We also obtained preliminary data in the only mouse
cell line tested, N2a (data not shown).
We also tested whether eliminating a crucial cation-π inter-
action, at the γ amino acid (Fig. S1), eliminates nicotine-induced
ΔF. In experiments on puriﬁed iAChSnFR, we found that the
F357A mutation abolished sensitivity to ACh. In the present
experiments, the equivalent mutation, iNiSnFR3a_Y357A_PM,
was constructed and tested in HeLa cells. We found no detect-
able nicotine-induced ΔF at concentrations ≤300 µM (Fig. 5 F).
This observation also provides assurance that the nicotine-
induced ΔF has little or no nonselective component.
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Nicotine enters the ER of neurons
Fig. 6 analyzes ﬂuorescence induced by nicotine at two variants
of iNicSnFR3 expressed in neurons. An AAV2 construct yielded
basal ﬂuorescence in >50% of cultured mouse hippocampal
neurons, and each ﬂuorescent cell also showed responses to
nicotine within a few seconds after an increase or decrease of
extracellular nicotine. Interestingly, neurons yield roughly
the same ΔF/F0 values for iNicSnFR3b_PM and iNicSnFR3b_ER.
A similar pattern of roughly equal nicotine-induced ΔF/F0
in neurons was observed for cDNA transfection, with
iNicSnFR3a_PM and iNicSnFR3a_ER. As usual for neuronal
cultures, cDNA transfection led to sparser expression (<10% of
cells) than viral transduction.
Dopaminergic neurons of the reward pathway located in the
ventral tegmental area play a role(s) in nicotine addiction
(Subramaniyan and Dani, 2015). Studies also suggest that nico-
tine protects dopaminergic neurons of the substantia nigra pars
compacta during the initial stages of Parkinson’s disease, via an
inside-out pathway (Srinivasan et al., 2014, 2016; Henderson
et al., 2016). Therefore, we assessed the entry of nicotine into
the ER of human dopaminergic neurons differentiated from
iPSCs.
It is not yet routinely possible to speciﬁcally induce either
ventral tegmental area–like or substantia nigra pars compacta–
like dopaminergic neurons from iPSCs; therefore, we recorded
ﬂuorescence from all neurons expressing iNicSnFR3a_ER (Fig. 6,
E and F). The data show recordings resembling those recorded
from other cell types. The ﬂuorescence reaches steady-state
within a few seconds after nicotine appears near the cells and
decays to F0 within a few seconds after removal. The ΔF/F0
values reach a maximum of 3–4, and the [nicotine] giving half-
ΔFmax/F0 is on the order of 20 µM.
We also found that viral transduction with AAV2-
iNicSnFR3b_ER proceeded efﬁciently in the induced iPSC cul-
tures (Fig. S5). >90% of the neurons were ﬂuorescent, and all of
these gave detectable increases in the presence of nicotine. The
responses resembled those for transfected dopaminergic neu-
rons but had lower ΔF/F0, rarely exceeding 2. In two cells, we
Figure 5. Dose–response relations for
nicotine-induced ΔF in HeLa cells. Exemplar
data for iNicSnFR3a_PM and iNicSnFR3a_ER
expressed in transfected HeLa cells. (A and C)
20-s nicotine dose application followed by 20-s
wash in HBSS. The average response for three
cells at each dose is overlaid in a 30-s window
for the PM and ER traces in A and C, respectively.
The SEM is shown as colored bands. (B and D)
The averaged ΔF/F0 at each response in A and C,
respectively, is plotted against the logarithmic
concentration scale with SEM given as error
bars. (E) Comparisons among nicotine itself,
N’MeNic, and ACh; experiments in transfected
HeLa cells. The iNicSnFR3a_PM responses to
ACh and to N’MeNic were normalized to
NicSnFR3a_PM responses for nicotine (100 µM).
The iNicSnFR3b_ER responses to ACh and to
N’MeNic were normalized to iNicSnFR3b_ER
responses for nicotine (100 µM). Note that
iNIcSnFR3a_PM responds robustly to all three
ligands, but only iNicSnFR3b_ER responds ro-
bustly only to nicotine, the only permeant mol-
ecule among the three tested. (F) Mutating a
probable cation-π interacting residue, Tyr357,
eliminates nicotine-induced ΔF. Exemplar data
from cells transfected in parallel and tested on
the same day.
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found that ΔF induced by N’MeNic (100 µM) was <0.2 times
as large as ΔF induced by 1 µM nicotine. This conﬁrms that
iNicSnFR3b_ER senses only intracellular nicotine, as found for
expression in HeLa cells (Fig. 5).
[Nicotine] in the ER approximately equals [nicotine] at the PM
To assess the relationship between [nicotine] in the ER versus
[nicotine] applied in the extracellular solution, we compared the
increase of ΔF/F0 versus applied [nicotine], as measured by the
_ER and _PM constructs. Two cell types (HeLa and hippocampal
neurons) provided complete datasets with both _ER and _PM
constructs (presented in Fig. 5 and Fig. 6, A–D). For this analysis,
we accepted data for applied [nicotine] ≤ 5 µM, because this
concentration range is most pharmacologically relevant, well
below the EC50, and least subject to pH perturbation in the ER.
The appropriate metric is deﬁned as [ΔF/F0]/[nicotine] and has
the units µM−1. For measurements with the _ER constructs and
for the _PM constructs, the metric is 0.075 ± 0.019 µM−1 and
0.063 ± 0.13 µM−1, respectively (mean ± SEM, n = 8 cells in each
case; Fig. 6 F inset, gives an exemplar plot). This similarity
shows that [nicotine] in the ER is approximately equal to [nic-
otine] applied in the external solution. Less complete data show
a similar pattern in other cell types: SH-SY5Y (Fig. S4 A),
HEK293 (Fig. S4 B), and human dopaminergic neurons differ-
entiated from iPSCs (Fig. 6, E and F; and Fig. S5).
For purposes of the simulations described in a later section,
we assumed that [nicotine] is equal in the ER and in the extra-
cellular solution. We interpret “approximately equal” as a dif-
ference of less-than twofold. The uncertainty arises primarily
because of differences between the pH of the ER and extracel-
lular solution. In most estimates, this difference is <0.2 pH units
(Casey et al., 2010), but has not been measured for the cell types
we investigated. As noted, it is unlikely that nicotine and vare-
nicline at the sub-µM concentrations of most interest perturb
the pH of the ER. Such perturbation (for instance, by mito-
chondrial uncouplers; Mitchell, 1966) requires that both the
uncharged and charged form of the drug can permeate through
membranes, either passively or via transporters(s). All previous
studies on nicotine conclude that only the uncharged form is
membrane-permeant (Lester et al., 2009).
Figure 6. Nicotine in the ER of neurons.
(A–D) Exemplar nicotine-induced ﬂuorescence
increases for cultured hippocampal neurons
transduced with AAV2/1.sin1.iNicSnFR3b_PM (A
and B) or with AAV2.sin1.iNicSnFR3b_ER (C and D).
(A and C) 20-s nicotine pulses, followed by 20-s
wash in HBSS. The average waveform for ﬁve cells
at each [nicotine] is overlaid for the PM and ER
traces in A and C, respectively. The SEM is shown as
colored bands around each line. Dose–response
relations are shown in B and D. (E and F) Human
dopaminergic neurons transfected with iNicSnFR_ER3a.
(E) Typical nicotine-induced ﬂuorescence during
20-s pulses of nicotine at the indicated concen-
trations. Data were subjected to a triangle ﬁlter
(half-time, 1 s). (F) Full dose–response data from
20 transfected human dopaminergic neurons.
Inset, start of the dose relation at [nicotine] ≤
5 µM. The slope of the line, [ΔF/F0]/[nicotine], is
0.087 µM−1.
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Micro-iontophoresis of nicotine: membrane permeation does not
slow ﬂuorescence increases
Results presented above show that a “jump” of [nicotine] in the
external solution results in ΔF in the ER. We asked whether the
kinetics of ΔF reveal any delay due to diffusion of nicotine across
either the PM or the ER membrane. To decide this point, we
obtained more rapid application of nicotine without complica-
tions from solution changes or pH changes. We delivered nico-
tine from micro-iontophoretic pipettes (Del Castillo and Katz,
1955). The data (Fig. 7) show that, for a cell within 10 µm of
the pipette tip, iNicSnFR3b_ER produces ﬂuorescence increases
within <1 s, approximately equal to the response time of the
iNicSnFR itself (Fig. 2 D). This result shows that the PM and the
ER membrane do not present a detectable diffusion barrier on
this time scale. For more distant cells, the ﬂuorescence increase
is slower and smaller. For instance, the cell in ROI 3, ∼150 µm
from the tip of the micro-iontophoretic pipette, responded
completely on a time scale of ∼10 s. This is consistent with a
diffusion constant on the order of 1 µm2/ms.
It is not possible to quantify the [nicotine] ejected from the
tip of an iontophoretic pipette. We conducted dose–response
studies by varying the iontophoretic current between 10 nA (as
shown in Fig. 7) and 100 nA. As the current was increased, the
ΔF/F0 for the cell in ROI 1 did not increase; the response in the
cell of ROI 2 increased modestly and became faster, to equal
the value in ROI 1. The cell in ROI 3 increased more gradually,
eventually reaching ΔF/F0 ∼0.3 at an ejection current of 100 nA.
Simulations of the outside-in and inside-out pathways
during smoking
Our data generate two insights important for understanding the
inside-out pathway. First, the genetically encoded nicotine bio-
sensors targeted to the ER reveal that nicotine appears in the ER
within ≤10 s after it appears in the extracellular solution. The
delay may be as small as 1 s, but this distinction has no impor-
tance for the simulations in this section. Second, after this delay,
the [nicotine] in the ER differs by less than twofold from [nic-
otine] in the extracellular solution.
The most complete data on pharmacological chaperoning
have used extracellular nicotine, applied for several hours
(Kuryatov et al., 2005). Therefore, a major question arising from
previous data were whether nicotine enters the ER quickly
enough to serve as a pharmacological chaperone. The answer,
based on our present data, is clearly, “yes.” It is reassuring, but
not crucial, to know that [nicotine] in the ER is rather close to
that outside the cell, so that the highest-afﬁnity states of
nicotine-nAChR binding, which leads to pharmacological
chaperoning, need not differ drastically from events at the PM.
A question of particular interest now arises about the exit of
nicotine from the ER. When nicotine is removed from the ex-
tracellular solution, nicotine leaves the ER, again within 10 s. If
[nicotine] in the ER drops below the EC50 for pharmacological
chaperoning during the interval between cigarettes, then the
inside-out pathway cannot readily account for nicotine depen-
dence. We term this point the “rapid exit” problem.
The rapid exit problem may be addressed by existing data on
the pharmacokinetics of nicotine during smoking. After a person
receives a bolus of nicotine from a cigarette or an ENDS, [nic-
otine] in the body decreases with two exponential terms. During
the slower phase, measurable nicotine endures in the plasma for
several hours (Benowitz et al., 1991). We simulated fractional
activation of the inside-out and outside-in pathways using the
available data from the literature (Benowitz et al., 1991; Kuryatov
et al., 2005; Rollema et al., 2007). We assume a common pattern
of smoking: one cigarette, yielding 1 mg of ingested nicotine,
each hour, for 12 h during each day (Table 1). The detailed pa-
rameters of the simulation are given in Table S2.
The simulations show how plasma/cerebrospinal ﬂuid (CSF)/
ER nicotine concentration varies on the time scale of minutes to
hours (Fig. 8 B1). Clearly, [nicotine] in the ER remains greater
than the EC50 for pharmacological chaperoning during the entire
1-h interval between cigarettes. The inside-out pathway remains
substantially activated continually during the 12–16 smoking-
period hours of our simulations (Fig. 8 B2).
Studies with varenicline in vitro and in live cells
In addition to detecting nicotine, the biosensors iNicSnFR3a and
iNicSnFR3b also detect varenicline (Fig. 9 and Fig. S6). In ﬂuo-
rescence data, puriﬁed iNicSnFR3a displays a varenicline EC50
approximately sixfold less than for nicotine. The maximal re-
sponse, ΔFmax/F0, is at least equal to that for nicotine (Fig. 9 A).
Note that the ﬁtted Hill coefﬁcient is signiﬁcantly less than
unity, as also noted for the live-cell imaging described below.
Biochemical characterization also indicates that varenicline
binds more strongly than nicotine to iNicSnFR. The stopped-
ﬂow kinetics (Fig. 9 B) reveal smaller pseudo–ﬁrst-order for-
ward and reverse rate constants (kon and koff, respectively) than
for nicotine (Fig. 2 D), as well as an inferred equilibrium binding
Figure 7. Micro-iontophoretic nicotine ap-
plication. (A) Cultured mouse hippocampal
neurons transducedwith AAV_iNicSnFR3b_ER. A
nicotine-containing micro-iontophoretic pipette
was positioned <10 µm above the cell in ROI 1.
A 10-nA outward current pulse (32-s duration)
was delivered. Most cells in the area showed
ﬂuorescence increases. (B) Fluorescence traces
recorded simultaneously for cells at three dis-
tances from the pipette.
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constant Kd, approximately threefold less than for nicotine
(compare with Fig. 2 D). The isothermal titration calorimetry
data for the varenicline–iNicSnFR3a interaction (Fig. 9 C) also
reveal a several-fold lower Kd (3.5 µM) than for nicotine.
Varenicline enters the ER
Live-cell imaging shows robust dose-dependent, varenicline-
induced ﬂuorescence increases, both in HeLa cells and in neu-
rons, both at the PM and in the ER (Fig. 9 and Fig. S6). The
pharmacologically relevant varenicline concentrations are
<1 µM, a range that yields varenicline-induced ΔF. Unlike the
data for nicotine, the varenicline dose–response data for both
HeLa cells and neurons do approach saturation, allowing the
conclusion that the dose–response relations show an EC50 of
1–4 µM. This agrees well with the data on puriﬁed biosensor
protein.
Especially in neurons, the growth and decay phases of the ER
varenicline-induced ﬂuorescence (Fig. 9 F and Fig. S6 C) are
clearly slower than either the nicotine responses presented
earlier or the varenicline responses on the PM (Fig. 9 D and
Fig. S6 A). The relatively slow ER varenicline responses occur
even for the smallest measured [varenicline] (≤ 1 µM), which
are unlikely to perturb organellar pH. The slower ER entry and
exit for varenicline than for nicotine are consistent with the
lower logD7.4 (−1.27 vs. −0.04; Smith et al., 2012), as though
the ER entry/exit of varenicline is rate-limited by membrane
permeability.
Pharmacokinetic and pharmacodynamic simulations of varenicline
The data show that varenicline does enter the ER within <30 s
after appearing near cells and that varenicline then leaves the ER
within at most 60 s after leaving the external solution, at the
clinically relevant sub-µM concentrations. These data are ade-
quate to add a subcellular dimension to pharmacokinetic simu-
lations for orally administered varenicline. We used a model
appropriate to twice-daily oral administration and with pa-
rameters that account for the very different absorption and
metabolism of varenicline (Fig. 10) versus nicotine (Fig. 8 and
Table S2). The simulations show that the usual doses of vare-
nicline only slightly activate the outside-in pathway of nAChR
activation. In contrast, varenicline activates the inside-out
pathway of pharmacological chaperoning by >50% after the
second dose of varenicline and by >70% after the ﬁfth dose.
Discussion
The study quantiﬁes the dynamics and extent of an early step in
the inside-out pathway for nicotine: entry into the ER. Down-
stream steps have been studied and quantiﬁed in several a
previous report using biochemistry, ﬂuorescence microscopy,
genetically alteredmice, and immunocytochemistry (Henderson
and Lester, 2015).
Development of the iNicSnFR family begins the ﬁeld of op-
tical subcellular pharmacokinetics for nicotine. We present data
that extend to the sub-µM nicotine concentration that exists in
the plasma and CSF of a smoker or vaper. The genetically en-
coded nicotine biosensors iNicSnFR3a and -3b, trapped in the
ER, reveal that nicotine appears in the ER within at most 10 s
after it appears in the extracellular solution (Fig. 5, Fig. 6, Fig. 7,
Fig. S4, and Fig. S5). The [nicotine] in the ER is equal to that in
the extracellular solution, at a precision of twofold. These con-
clusions hold for each of the ﬁve cell types we have investigated:
three types of human clonal cell lines (HeLa, Fig. 5; SH-SY5Y,
Fig. S4 A; and HEK293, Fig. S4 B), human dopaminergic neurons
differentiated from iPSCs (Fig. 6, E and F; and Fig. S5), and
mouse hippocampal neurons (Fig. 6, A–D; and Fig. 7).
Fluorescent biosensors for optical
subcellular pharmacokinetics
Our strategy (Fig. 1) extends that used for iGluSnFR (Marvin
et al., 2013). No known natural PBP binds nicotine; therefore,
we engineered a PBP to bind a drug. That NicSnFRs also rec-
ognize Ach, and more weakly, choline, is useful for studies of
compartmentalization. Related OpuBC proteins, further opti-
mized to sense ACh itself, will also ﬁnd use in neuroscience
(Borden et al., in preparation).
Although the directed evolution of the iNicSnFR family (Fig.
S2) did not explicitly include assays for varenicline, varenicline
is a highly potent full agonist for iNicSnFR3 ﬂuorescence. In-
terestingly, varenicline is also more potent than ACh at both
α4β2 and α7 nAChRs (Coe et al., 2005; Mihalak et al., 2006).
However, varenicline is a full agonist at α7, but not at α4β2
nAChRs. Thus, there are differences in the details of the binding
site of the iNicSnFR constructs versus nAChRs. We found that
the iNicSnFR3a and iNicSnFR3b constructs are less sensitive to
other α4β2 agonists: cytisine, dianicline, and A-85380 (unpub-
lished data).
Other neuronal drugs may also operate via inside-out path-
ways (Jong et al., 2009; Lester et al., 2012, 2015). With further
Table 1. Effect of dosing regimen variations on simulated nicotine
concentrations in plasma/CSF/ER and on nAChR activation or
chaperoning
Nicotine
dose (mg)
per
cigarette
Total daily
cigarettes,
intervals
Average
[nicotine] in
plasma/
CSF/ER
(nM)
Average
nAChR
activation
on PM
Average
activation of
nAChR
chaperoning in
ER
1 12/d, 1 h 112 0.1 0.7
0.5 12/d, 1 h 56 0.05 0.55
0.3 12/d, 1 h 34 0.03 0.44
0.1 12/d, 1 h 11 0.01 0.2
0.05 12/d, 1 h 6 0.006 0.13
3 12/d, 1 h 321 0.23 0.83
1 6/d, 2 h 65 0.06 0.6
1 20/d, 0.8 h 148* 0.13* 0.75*
Results have been averaged over 12 or 16 h. Asterisk (*) denotes 16-h
average. The ﬁrst row (in bold) presents our deﬁnition of a standard habit,
plotted in Fig. 8. The following ﬁve rows show simulations for increasingly
“denicotinized” cigarettes. The row presenting a dose of 3 mg might be
appropriate for a schizophrenic’s smoking strategy (Miwa et al., 2011).
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modiﬁcations to the ligand site, preliminary data show that it
may be possible to develop families of biosensors for optical
subcellular pharmacokinetics of several amine-containing drug
classes (Muthusamy et al., 2018; Shivange et al., 2017. Annual
Meeting of the Society of General Physiologists. Abstract no. 32.
J. Gen. Physiol.). Values for logD7.4 of most neural drugs suggest
that they enter organelles (Lester et al., 2012; Nickell et al., 2013;
Jong et al., 2018), and melatonin probably also enters neutral
organelles (Yu et al., 2016). The most important limitation, at
present, is the extreme pH sensitivity of the biosensors. This
constrains their usefulness in acidic organelles, where some
neuronal drugs may also act (Stoeber et al., 2018).
Another class of ﬂuorescent protein-based biosensors is de-
rived from GPCRs rather than from PBPs (Jing et al., 2018;
Patriarchi et al., 2018). In the GPCR-based biosensors, the ligand
sites face the extracellular solution; they would presumably face
the lumen of organelles like most (but not all) PBP-based SnFRs.
However, in the GPCR-based biosensors, the ﬂuorescent protein
moiety faces the cytosol and therefore might be relatively in-
sensitive to luminal pH. If GPCR-based biosensors can function
in acidic organelles, they may also ﬁnd use for subcellular
pharmacokinetics.
Implications for the inside-out pathway
Our data show that when [nicotine] in the extracellular solution
falls to zero, nicotine completely leaves the ER, again within 10 s.
Yet after a person receives a bolus of nicotine from a cigarette,
[nicotine] in the body does not immediately fall to zero. The
rather leisurely metabolism of nicotine (half-time, ∼20 min in
humans; Benowitz et al., 1991) provides that a smoker’s CSF
[nicotine] decreases on the time scale shown in Fig. 8 B1. Because
of the highly nicotine-sensitive feature of pharmacological
Figure 8. Simulations of nicotine pharmaco-
kinetics and pharmacodynamics during
smoking. (A) The pharmacokinetic/pharmaco-
dynamic model, implemented in Matlab SimBi-
ology. Individual parameters and structures and
smoking dosages are presented in Table S2 and
in Supplemental ZIP File. (B1) Nicotine concen-
trations in the plasma/CSF/ER and in the “se-
questered” compartment, during 40 simulated
hours for the standard habit (Table S2 and
Supplemental ZIP File). The latter compartment
was termed the “peripheral compartment” by
Benowitz et al. (1991), but that terminology is
less preferable in discussions of the nervous
system. Note the logarithmic [nicotine] scale.
(B2) Effects on the two processes shown in A.
Note that the standard habit nearly activates
nAChR protein chaperoning (inside-out process)
>50%, but activates nAChR channel activation
(outside-in process) <20%.
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chaperoning, [nicotine] in the ER remains greater than the EC50
for pharmacological chaperoning during the entire 0.75–1-h in-
terval between cigarettes. The inside-out pathway remains
>50%-activated continually during the 12–16 h of our simu-
lations (Fig. 8 B2). We conclude that the inside-out pathway,
operating via pharmacological chaperoning, can readily account
for up-regulation, an important component of nicotine
dependence.
Our simulations also lead one to reexamine the relationship
between the previously distinct concepts of “acute,” “repeated,”
and “chronic” exposure to nicotine. In the “standard habit,” even
a single cigarette, whose nicotine is fully ingested during 10min,
activates the inside-out pathway >50% until the next cigarette
1 h later (Fig. 8). Thus, a series of “acute” and “repeated” ex-
posures, one per hour for 12 h, becomes “chronic” activation for
the 12 h of smoking activity. By the next morning, nicotine levels
have decreased below levels that activate pharmacological
chaperoning; but the downstream trafﬁcking and subsequent
sequelae, including nAChR up-regulation, probably endure for
several days (Marks et al., 1985).
Thus, subcellular pharmacokinetics readily explains depen-
dence on smoked nicotine. Around the world at any time, sev-
eral 100 million people have ingested tobacco within the past
hour; they retain nicotine in every organelle of every cell.
In the ER and cis-Golgi of the small percentage of cells that
contain α4β2 nAChRs, these levels activate the inside-out
pathway >50%, and therefore maintain one aspect of nico-
tine dependence.
Recently introduced ENDSs provide plasma levels with ki-
netics approaching those of cigarettes (Bowen and Xing, 2015).
Thus, ENDSs can also maintain a key molecular/cellular basis of
nicotine dependence: the inside-pathway at α4β2 nAChRs.
Can outside-in mechanisms, such as channel activation and
Ca2+ inﬂux, also account for cellular/molecular aspects of nico-
tine dependence? In contrast to pharmacological chaperoning,
nAChR channels do not remain fully activated during the aver-
age smoker’s day; in fact, the average activation of PM nAChR
channels is <20% (Fig. 8 B2). Some explanations of nicotine
dependence assume that Ca2+ inﬂux, either directly through
nAChRs or indirectly through neuronal activity-induced Ca2+
channel inﬂux, can account for nicotine addiction, even con-
sidering the rather modest level of nAChR channel activation
shown by our simulations. Yet the rather general phenomenon
of Ca2+ inﬂux has not been shown to account for the highly
speciﬁc aspects of nicotine addiction, such as post-translational
nAChR up-regulation. Another frequently invoked explanation
Figure 9. Varenicline activity against puriﬁed
iNicSnFR3a (A–C) and iNicSnFR3b expressed
in hippocampal neurons (D–G). (A) Dose–
response relations for varenicline-induced ΔF/
F0, measured in 3× PBS, pH 7.4. Mean ± SEM;
three measurements. (B) Stopped-ﬂow measure-
ments at various [varenicline]. (C) Isothermal
titration calorimetry. (D–G) Exemplar varenicline-
induced ﬂuorescence increases for cultured hip-
pocampal neurons transduced with AAV2/1.syn1.-
iNicSnFR3b_PM (D and E) or with AAV2/
1.syn1.iNicSnFR3b_ER (F and G). (D and F) 30-s
varenicline pulses, followed by 40-s wash in HBSS.
The average waveform for ﬁve cells at each [var-
enicline] is overlaid for the PM and ER traces in A
and C, respectively. The SEM is shown as colored
bands around each line. (E and G) Dose–response
relations, ﬁtted to a single-component Hill equa-
tion, including zero response at zero [varenicline].
Parameters are shown.
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for nicotine dependence is desensitization of nAChR channels
in response to the presence of nicotine. It is highly likely that
some acute aspects of nicotine exposure arise from desensitiz-
ation rather than activation (Miwa et al., 2011). However, no
available data suggest that desensitized nAChRs begin an in-
tracellular signaling pathway that could account for nicotine
dependence.
Implications for varenicline-based therapy
The present data show that varenicline also enters the ER (Fig. 9
and Fig. S6), and the simulations show that the resulting
maintained level of varenicline in the ER could lead to phar-
macological chaperoning by varenicline (Fig. 10). This explains
the observations that varenicline also up-regulates α4β2 nAChRs
(Turner et al., 2011; Marks et al., 2015; Govind et al., 2017). The
usual explanation for varenicline as a smoking cessation agent is
that, even though it produces negligible activation of α4β2
nAChR channels (Fig. 10 B2), it does desensitize these nAChRs,
blocking the action of nicotine itself. Our study supports the
additional suggestion that the several-week taper regimen for
varenicline also allows nicotine users to reverse up-regulation
gradually. This, in turn, could help aspiring quitters to avoid
craving and/or behavioral aspects of withdrawal. However, the
persistence of up-regulated nAChRs could also cause some of the
side effects of varenicline during the ﬁrst days to weeks (Ashare
et al., 2017); these side effects could underlie this drug’s modest
effectiveness in smoking cessation (Fagerstro¨m and Hughes,
2008).
Nicotine may also be neuroprotective in Parkinson’s dis-
ease, and this effect may proceed via an inside-out pathway
in the ER (Srinivasan et al., 2014, 2016). Therefore, we note
recent reports that varenicline also displays neuroprotective
effects in animal models of Parkinson’s disease (McGregor
et al., 2017) and another neurodegenerative disease (Sharma
et al., 2018).
Quantitative aspects of reducing nicotine levels
The prominence of the inside-out pathway in nicotine de-
pendence has prompted us to simulate the activation of the
inside-out pathway, as well as the outside-in pathway, during
use of modiﬁed tobacco or ENDS (Table 1). United States
Food and Drug Administration ofﬁcials recently suggested
decreasing the nicotine content of combustible tobacco. Our
simulations show that a 3-fold reduction would nonetheless
provide >40% average activation of the inside-out pathway; a
10-fold reduction (to 0.1 mg/cigarette) would reduce average
activation to 20%. This conclusion would also hold for inges-
tion via an ENDS.
Our simulations deal with a “typical” smoker (Benowitz et al.,
1991). These conclusions must be modiﬁed, at a personal level,
for each smoker or vaper. Polymorphisms in cytochrome P450
2A6, the enzyme that primarily metabolizes nicotine, lead to
dramatic (up to 10-fold) differences in nicotine lifetime among
people (Dempsey et al., 2004). These result, in turn, to differ-
ences in the frequency of smoking (Tanner et al., 2015). Future
investigations must simulate the consequences of these varia-
tions for activation of the inside-out pathway.
If a nicotine-dependent person perceives desirable effects
from up-regulated nAChRs, he or she might therefore prefer to
inhale nicotine from an ENDS capable of delivering 1 mg of
nicotine within a few minutes, rather than from a modiﬁed
cigarette that, along with harmful smoke, delivers <0.1 mg, a
dose that does not maintain full up-regulation. The harm re-
duction that results from such an individual behavioral choice
about nicotine intake, (1) if stringently maintained by the
nicotine-dependent individual and (2) if replicated in the entire
nicotine-dependent population, would be considerable. One re-
view suggests that such a complete transition would decrease
tobacco-related diseases by 95% (Royal College of Physicians,
2016). Whether and how a society wishes to encourage such a
transition from smoked tobacco to ENDS involves details both of
policy and of science.
Figure 10. Simulated pharmacokinetics and pharmacodynamics during
oral varenicline administration. (A) In the pharmacokinetic model for orally
administered varenicline, the lungs are replaced by the digestive tract. The
parameters derive from studies on humans (Faessel et al., 2006). The pa-
rameters are given in Table S2 and in Supplemental ZIP File. (B1) Varenicline
concentrations in two compartments: the plasma/CSF/ER and the seques-
tered compartment. (B2) Effects on the two processes shown in A. Note that
recommended treatment with varenicline almost completely activates nAChR
protein chaperoning (inside-out process), but only slightly produces nAChR
channel activation (outside-in process).
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